While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. in Anthropology and Natural Sciences and an M.S. He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. Jess'sprimary responsibility is to direct a concerted effort to analyze, design, and shape internal and external narratives. Sri Mahendra is a Senior Software Engineer at RA Capital Management. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. Prior to Blueprint Medicines, he spent two years at Lonza Pharma & Biotech, most recently as Product Development Scientist. This is a re-publication of an op-ed that first appeared in the Wall Street Journal on September 30, 2018 and is now included in The Biotech Social Contract series of . Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. Prior to RA, Fuad was a Flagship Labs Fellow at Flagship Pioneering. Senior Research Assistant, Venture Analytics. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. Peter Pan Is The Real Villain: Disney Supports The Evil Peter Pan Theory Alexs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. 4. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. Vanderpump Rules' Peter Madrigal's Age. Brigid holds a BS in Chemistry (Hons) from the Commonwealth Honors College at the University of Massachusetts, Amherst (2002) and a PhD in Materials Science and Engineering from Johns Hopkins University (2009). He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. Brendans primary responsibility is managing all aspects of the tax function. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Kevin has a ME in Chemistry and Chemical Engineering from Chimie ParisTech in France, a MS in Biotechnology from the Royal Institute of Technology in Sweden, and a PhD in Physics and Chemistry from Paris Sciences et Lettres Research University in France. Matt Beverly is a Senior Software Engineer at RA Capital Management. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. Daniel Slesinski is an Associate within the Planetary Health division at RA Capital Management. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. Josh was previously co-lead of SV Health Investors US Biotech practice where he was responsible for SVs US venture creation activities, including its incubator, Brahma Discovery. Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. As Engagement Associate at RA Capital Management, Thomas Culman leverages qualitative and quantitative skills to manage a variety of educational, outreach, and advocacy-oriented projects. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. The 30-Year-Old CEO Conjuring Drug Companies From Thin Air - Forbes She is a Clinical Reader at Kings College London with a laboratory working on translational adaptions to CAR T cell engineering to optimize clinical utility. Peter Kolchinsky, Founder and Managing Director of RA Capital Management, L.P. and Founder of the nonprofit No Patient Left Behind, sits down with Liked by Peter Kolchinsky We need YOU to help. Her graduate research investigated synaptic translation in syndromic autism. However he's a bit older than others, like Raquel Leviss, who is only 28 . Jaimie's primary responsibilities are to coordinate calendars, events, and company meetings for RA Venture Partners and EIRs. In addition, he designs graphics for all internal and external materials. James Schneider is the Deputy General Counsel at RA Capital Management. In this role, Emily works closely with senior leaders, Venture Partners and Managing Directors within the Venture Team at RA Capital and within RAVen. During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. GREENWICH Peter Crumbine, a mainstay of public service in Greenwich for decades whose level-headed, friendly and professional manner earned . Prior to joining RAVen, Habib spent five years as President and CEO at Acceleron Pharma. Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Her doctoral research investigated the folding and aggregation of gamma-crystallins associated with cataract formation. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. By continuing, you accept the use of these cookies. Maryann received her Bachelor of Science in English from Northeastern University. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. In his most recent role as Entrepreneur In Residence and Head of Computation at RA Ventures (RAVen), Soumya Ray supported the creation of two RAVen-incubated newcos. From 2016-2017, Scott served as President of Sojournix, Inc., an asset-focused biopharmaceutical company that he co-founded and served as Board member until 2021. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. Mariagrace previously worked as an Executive Assistant at MPM Capital. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities.